Positive panel for PNU's Camptosar

The FDA's Oncologic Drugs Advisory Committee unanimously recommended for approval Camptosar irinotecan, a topoisomerase I inhibitor developed by Pharmacia & Upjohn (PNU), as a first-line treatment for...